

F Cardoso

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5598404/f-cardoso-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

17,564
citations

58
h-index

132
g-index

184
ext. papers

20,531
ext. citations

4.4
avg, IF

6.21
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 166 | Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101918 | 2.2 | 2 |
| 165 | Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102019 | 2.2 | 4 |
| 164 | Quality-of-life methodology in hormone receptor-positive advanced breast cancer: Current tools and perspectives for the future. <i>Cancer Treatment Reviews</i> , 2021 , 102, 102321 | 14.4 | 1 |
| 163 | Breast cancer surgery with augmented reality. <i>Breast</i> , 2021 , 56, 14-17 | 3.6 | 8 |
| 162 | Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 399-410 | 4.4 | 2 |
| 161 | Gaps in Care and Support for Patients With Advanced Breast Cancer: A Report From the Advanced Breast Cancer Global Alliance. <i>JCO Global Oncology</i> , 2021 , 7, 976-984 | 3.7 | 0 |
| 160 | Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 98 | 7.8 | 1 |
| 159 | PARP inhibitors coming of age. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 69-70 | 19.4 | 6 |
| 158 | Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto. <i>Breast</i> , 2021 , 55, 128-135 | 3.6 | 5 |
| 157 | CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer. <i>Breast</i> , 2021 , 55, 75-78 | 3.6 | 5 |
| 156 | Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. <i>Breast</i> , 2021 , 55, 79-90 | 3.6 | 5 |
| 155 | Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021 , 59, 327-338 | 3.6 | 5 |
| 154 | Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy. <i>Communications Biology</i> , 2020 , 3, 299 | 6.7 | 16 |
| 153 | The requirements of a specialist breast centre. <i>Breast</i> , 2020 , 51, 65-84 | 3.6 | 47 |
| 152 | ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020 , 31, 674-696 | 10.3 | 80 |
| 151 | Regularization Techniques in Radiomics: A Case Study on the Prediction of pCR in Breast Tumours and the Axilla. <i>Lecture Notes in Computer Science</i> , 2020 , 271-281 | 0.9 | |
| 150 | A multi-stakeholder approach in optimising patientsNeeds in the benefit assessment process of new metastatic breast cancer treatments. <i>Breast</i> , 2020 , 52, 78-87 | 3.6 | 1 |

| | | | |
|-----|---|------|-----|
| 149 | An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. <i>Annals of Oncology</i> , 2020 , 31, 283-288 | 10.3 | 17 |
| 148 | 3D digital breast cancer models with multimodal fusion algorithms. <i>Breast</i> , 2020 , 49, 281-290 | 3.6 | 5 |
| 147 | Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. <i>European Journal of Cancer</i> , 2020 , 125, 69-82 | 7.5 | 14 |
| 146 | Putting words into practice. <i>Breast</i> , 2020 , 49, 171-173 | 3.6 | 1 |
| 145 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020 , 31, 1623-1649 | 10.3 | 282 |
| 144 | Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial. <i>Communications Biology</i> , 2020 , 3, 397 | 6.7 | 1 |
| 143 | New strategies for the precision treatment of HER2-driven tumours. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019 , 4, 239-249 | 1.6 | |
| 142 | Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2019 , 30, 365-373 | 10.3 | 55 |
| 141 | Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019 , 30, 1194-1220 | 10.3 | 528 |
| 140 | Targeting CDK4/6 pathways and beyond in breast cancer. <i>Breast</i> , 2019 , 43, 8-17 | 3.6 | 17 |
| 139 | Male breast cancer: a disease distinct from female breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 37-48 | 4.4 | 85 |
| 138 | Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). <i>Breast</i> , 2018 , 39, 131-138 | 13.8 | 100 |
| 137 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Annals of Oncology</i> , 2018 , 29, 405-417 | 10.3 | 153 |
| 136 | Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 977-984 | 13.4 | 33 |
| 135 | Immunohistochemical versus molecular (Blueprint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 123-131 | 4.4 | 39 |
| 134 | 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018 , 29, 1634-1657 | 10.3 | 645 |
| 133 | European Breast Cancer Conference manifesto on breast centres/units. <i>European Journal of Cancer</i> , 2017 , 72, 244-250 | 7.5 | 31 |
| 132 | An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint). <i>European Journal of Cancer</i> , 2017 , 75, 5-13 | 7.5 | 10 |

| | | | |
|-----|---|------|-----|
| 131 | Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). <i>European Journal of Cancer</i> , 2017 , 75, 284-298 | 7.5 | 265 |
| 130 | 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017 , 28, 16-33 | 10.3 | 241 |
| 129 | 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <i>Breast</i> , 2017 , 31, 244-259 | 3.6 | 137 |
| 128 | Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. <i>Cancer Treatment Reviews</i> , 2017 , 53, 98-110 | 14.4 | 73 |
| 127 | Reply to letter from Suguatti et al. <i>European Journal of Cancer</i> , 2017 , 87, 201-202 | 7.5 | |
| 126 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017 , 28, 1700-1712 | 10.3 | 586 |
| 125 | ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017 , 35, 203-217 | 3.6 | 163 |
| 124 | Research needs in breast cancer. <i>Annals of Oncology</i> , 2017 , 28, 208-217 | 10.3 | 47 |
| 123 | Review on the clinical use of eribulin mesylate for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 589-600 | 4 | 20 |
| 122 | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 463-9 | 4.4 | 19 |
| 121 | Second international consensus guidelines for breast cancer in young women (BCY2). <i>Breast</i> , 2016 , 26, 87-99 | 3.6 | 84 |
| 120 | Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys. <i>Breast</i> , 2016 , 28, 5-12 | 3.6 | 38 |
| 119 | Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. <i>Cancer Treatment Communications</i> , 2016 , 6, S1-S10 | | 7 |
| 118 | Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. <i>Annals of Oncology</i> , 2016 , 27, v103-v110 | 10.3 | 202 |
| 117 | Challenges in optimizing care in advanced breast cancer patients: Results of an international survey linked to the ABC1 consensus conference. <i>Breast</i> , 2015 , 24, 623-9 | 3.6 | 8 |
| 116 | Breast cancer under age 40: a different approach. <i>Current Treatment Options in Oncology</i> , 2015 , 16, 16 | 5.4 | 43 |
| 115 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015 , 26 Suppl 5, v8-30 | 10.3 | 962 |
| 114 | Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) <i>Annals of Oncology</i> , 2015 , 26, 873-879 | 10.3 | 89 |

| | | | |
|-----|--|------|-----|
| 113 | Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1680-7 | 2.2 | 47 |
| 112 | Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014. <i>Lancet Oncology, The</i> , 2015 , 16, e137-47 | 21.7 | 26 |
| 111 | Breast cancer in 2014: A call back to reality!. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 67-8 | 19.4 | 3 |
| 110 | Mammographic screening detects low-risk tumor biology breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 103-11 | 4.4 | 44 |
| 109 | First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014 , 23, 209-26 | 3.6 | 108 |
| 108 | Time for more optimism in metastatic breast cancer?. <i>Cancer Treatment Reviews</i> , 2014 , 40, 220-8 | 14.4 | 44 |
| 107 | Small breast cancers: when and how to treat. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1129-36 | 14.4 | 6 |
| 106 | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014 , 23, 489-502 | 3.6 | 231 |
| 105 | High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. <i>Annals of Oncology</i> , 2014 , 25, 816-823 | 10.3 | 41 |
| 104 | A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). <i>Breast</i> , 2014 , 23, 663-9 | 3.6 | 8 |
| 103 | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) <i>Annals of Oncology</i> , 2014 , 25, 1871-1888 | 10.3 | 279 |
| 102 | Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. <i>European Journal of Cancer</i> , 2014 , 50, 1045-54 | 7.5 | 12 |
| 101 | Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. <i>Genomics Data</i> , 2013 , 1, 7-10 | | 3 |
| 100 | A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. <i>Cancer Treatment Reviews</i> , 2013 , 39, 457-65 | 14.4 | 41 |
| 99 | Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. <i>Breast</i> , 2013 , 22, 593-605 | 3.6 | 47 |
| 98 | International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. <i>Breast</i> , 2013 , 22, 203-10 | 3.6 | 66 |
| 97 | Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes. <i>Breast</i> , 2013 , 22, 682-90 | 3.6 | 40 |
| 96 | Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials. <i>Breast</i> , 2013 , 22, 370-3 | 3.6 | 3 |

| | | | |
|----|--|------|-----|
| 95 | Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 3-22 | 1.6 | 3 |
| 94 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi7-23 | 10.3 | 338 |
| 93 | Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. <i>Annals of Oncology</i> , 2013 , 24, 2985-9 | 10.3 | 18 |
| 92 | Autoimmune haemolytic anaemia in a patient treated with capecitabine. <i>Acta Clinica Belgica</i> , 2013 , 68, 135-7 | 1.8 | 1 |
| 91 | Reply to Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease Pby U. Gueth et al. <i>Annals of Oncology</i> , 2013 , 24, 557 | 10.3 | |
| 90 | Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , 2012 , 21, 20-6 | 3.6 | 24 |
| 89 | 1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012 , 21, 242-52 | 3.6 | 258 |
| 88 | Chemoprevention for breast cancer. <i>Cancer Treatment Reviews</i> , 2012 , 38, 329-39 | 14.4 | 22 |
| 87 | The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 27-33 | 1.6 | 1 |
| 86 | An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. <i>Breast</i> , 2012 , 21, 716-23 | 3.6 | 14 |
| 85 | The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. <i>European Journal of Cancer</i> , 2012 , 48, 3355-77 | 7.5 | 187 |
| 84 | Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii11-9 | 10.3 | 356 |
| 83 | Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. <i>British Journal of Cancer</i> , 2012 , 106, 1618-25 | 8.7 | 15 |
| 82 | Breast Cancer in Young Women ? a Clinical Challenge to Be Addressed in a Multidisciplinary Setting. <i>Breast Care</i> , 2012 , 7, 193-194 | 2.4 | 1 |
| 81 | HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2011 , 12, 1134-42 | 21.7 | 141 |
| 80 | Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. <i>Lancet, The</i> , 2011 , 377, 914-23 | 40 | 764 |
| 79 | Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 221-6 | 4.4 | 52 |
| 78 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011 , 22 Suppl 6, vi12-24 | 10.3 | 177 |

| | | | |
|----|---|------|-----|
| 77 | Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011 , 22 Suppl 6, vi25-30 | 10.3 | 75 |
| 76 | BRCA in breast cancer: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2011 , 22 Suppl 6, vi31-4 | 10.3 | 142 |
| 75 | Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 272-9 | 19.4 | 25 |
| 74 | Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. <i>British Journal of Cancer</i> , 2010 , 103, 1788-93 | 8.7 | 56 |
| 73 | Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v15-9 | 10.3 | 92 |
| 72 | International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 456-63 | 9.7 | 252 |
| 71 | 444 The EORTC 10041/BIG 0304 MINDACT trial is feasible: first results of the pilot phase. <i>European Journal of Cancer, Supplement</i> , 2010 , 8, 188 | 1.6 | 3 |
| 70 | Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. <i>Breast</i> , 2010 , 19, 388-95 | 3.6 | 62 |
| 69 | Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009 , 20 Suppl 4, 15-8 | 10.3 | 41 |
| 68 | High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5700-6 ^{2.2} | | 338 |
| 67 | International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1174-81 | 9.7 | 177 |
| 66 | Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. <i>Current Cancer Drug Targets</i> , 2009 , 9, 148-62 | 2.8 | 44 |
| 65 | The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 295-302 | 4.4 | 222 |
| 64 | Stemming resistance to HER-2 targeted therapy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2009 , 14, 55-66 | 2.4 | 52 |
| 63 | Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. <i>European Journal of Cancer</i> , 2009 , 45, 1201-1208 | 7.5 | 28 |
| 62 | MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2009 , 3, 193-205 | | 9 |
| 61 | Adjuvant Chemotherapy of Breast Cancer. <i>Breast Care</i> , 2009 , 4, 339-341 | 2.4 | |
| 60 | Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. <i>British Journal of Cancer</i> , 2008 , 98, 1500-7 | 8.7 | 38 |

| | | | |
|----|---|------|------|
| 59 | HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. <i>Annals of Oncology</i> , 2008 , 19, 223-32 | 10.3 | 27 |
| 58 | Adjuvant Systemic Therapy, Quo Vadis? Patient Selection, Prognostic and Predictive Factors. <i>Breast Care</i> , 2008 , 3, 392-394 | 2.4 | |
| 57 | Facts and controversies in the use of trastuzumab in the adjuvant setting. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 645-54 | | 13 |
| 56 | Recommendations for collection and handling of specimens from group breast cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5638-44 | 2.2 | 68 |
| 55 | Clinical application of the 70-gene profile: the MINDACT trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 729-35 | | 396 |
| 54 | Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1057-1057 | 2.2 | 8 |
| 53 | The MINDACT trial: the first prospective clinical validation of a genomic tool. <i>Molecular Oncology</i> , 2007 , 1, 246-51 | 7.9 | 97 |
| 52 | Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. <i>British Journal of Cancer</i> , 2007 , 96, 1504-13 | 8.7 | 629 |
| 51 | p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. <i>Annals of Oncology</i> , 2007 , 18, 997-1003 | 10.3 | 45 |
| 50 | Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. <i>Oncologist</i> , 2007 , 12, 253-70 | 5.7 | 75 |
| 49 | Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. <i>Clinical Cancer Research</i> , 2007 , 13, 3207-14 | 12.9 | 759 |
| 48 | Individualization of therapy using Mammaprint: from development to the MINDACT Trial. <i>Cancer Genomics and Proteomics</i> , 2007 , 4, 147-55 | 3.3 | 47 |
| 47 | Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1183-92 | 9.7 | 976 |
| 46 | Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 3042-51 | 6.1 | 51 |
| 45 | Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. <i>Oncologist</i> , 2006 , 11, 111-25 | 5.7 | 45 |
| 44 | Use of trastuzumab for the treatment of early stage breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 1153-64 | 3.5 | 13 |
| 43 | Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 540-51 | | 202 |
| 42 | Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 262-72 | 9.7 | 1485 |

| | | | |
|----|--|------|-----|
| 41 | Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself. <i>International Journal of Gynecological Cancer</i> , 2006 , 16 Suppl 2, 533-7 | 3.5 | 2 |
| 40 | Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. <i>Clinical Cancer Research</i> , 2005 , 11, 4393-9 | 12.9 | 87 |
| 39 | Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. <i>Annals of Oncology</i> , 2005 , 16, 1723-39 | 10.3 | 220 |
| 38 | Bringing molecular prognosis and prediction to the clinic. <i>Clinical Breast Cancer</i> , 2005 , 6, 61-76 | 3 | 30 |
| 37 | Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes. <i>Oncology Reports</i> , 2004 , 12, 701-7 | 3.5 | 18 |
| 36 | Facts and controversies in systemic treatment of metastatic breast cancer. <i>Oncologist</i> , 2004 , 9, 617-32 | 5.7 | 139 |
| 35 | Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II- α gene amplification and protein overexpression in locally advanced/metastatic breast cancer 2004 , 24, 201 | | 6 |
| 34 | Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. <i>International Journal of Oncology</i> , 2004 , 25, 1473-9 | 1 | 13 |
| 33 | Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004 , 92, 887-95 | 4.9 | 42 |
| 32 | Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. <i>Clinical Breast Cancer</i> , 2004 , 5, 364-9 | 3 | 12 |
| 31 | Targeting the ubiquitin-proteasome pathway in breast cancer. <i>Clinical Breast Cancer</i> , 2004 , 5, 148-57 | 3 | 35 |
| 30 | E1. Tailored systemic treatment for breast cancer: dream or reality?. <i>European Journal of Cancer, Supplement</i> , 2004 , 2, 2-5 | 1.6 | 2 |
| 29 | Challenges in breast cancer clinical trial design in the postgenomic era. <i>Current Opinion in Oncology</i> , 2004 , 16, 536-41 | 4.2 | 13 |
| 28 | Molecular profiling of head and neck tumors. <i>Current Opinion in Oncology</i> , 2004 , 16, 211-4 | 4.2 | 30 |
| 27 | Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9504-9504 | 2.2 | 3 |
| 26 | Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. <i>International Journal of Oncology</i> , 2004 , 24, 201-9 | 1 | 29 |
| 25 | Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1207-14 | 6.1 | 83 |
| 24 | Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. <i>Annals of Oncology</i> , 2003 , 14, 698-9 | 10.3 | 39 |

| | | | |
|----|---|------|-----|
| 23 | Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?. <i>Anti-Cancer Drugs</i> , 2003 , 14, 703-13 | 2.4 | 4 |
| 22 | Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. <i>Breast Cancer Research and Treatment</i> , 2003 , 77, 199-204 | 4.4 | 28 |
| 21 | New data on chemotherapy in the adjuvant setting. <i>Breast</i> , 2003 , 12, 373-8 | 3.6 | 12 |
| 20 | The best use of chemotherapy in the adjuvant setting. <i>Breast</i> , 2003 , 12, 522-8 | 3.6 | 9 |
| 19 | The pipeline of new anticancer agents for breast cancer treatment in 2003. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 48, 45-63 | 7 | 11 |
| 18 | Progress in systemic therapy for breast cancer: an overview and perspectives. <i>European Journal of Cancer, Supplement</i> , 2003 , 1, 56-69 | 1.6 | 10 |
| 17 | Non-endocrine systemic therapies in advanced breast cancer. <i>European Journal of Cancer, Supplement</i> , 2003 , 1, 287-298 | 1.6 | 2 |
| 16 | Use and abuse of taxanes in the management of metastatic breast cancer. <i>European Journal of Cancer</i> , 2003 , 39, 1978-89 | 7.5 | 21 |
| 15 | Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. <i>Annals of Oncology</i> , 2003 , 14, 1419-24 | 10.3 | 29 |
| 14 | Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. <i>Annals of Oncology</i> , 2003 , 14, 1346-63 | 10.3 | 78 |
| 13 | Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. <i>International Journal of Clinical Oncology</i> , 2002 , 7, 245-53 | 4.2 | 9 |
| 12 | Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. <i>Breast Cancer Research and Treatment</i> , 2002 , 74, 113-20 | 4.4 | 62 |
| 11 | Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. <i>Annals of Oncology</i> , 2002 , 13, 197-207 | 10.3 | 110 |
| 10 | The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. <i>Annals of Oncology</i> , 2002 , 13, 416-21 | 10.3 | 5 |
| 9 | Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. <i>Annals of Oncology</i> , 2002 , 13, 1036-43 | 10.3 | 246 |
| 8 | Resistance to trastuzumab: a necessary evil or a temporary challenge?. <i>Clinical Breast Cancer</i> , 2002 , 3, 247-57; discussion 258-9 | 3 | 54 |
| 7 | Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. <i>Clinical Breast Cancer</i> , 2002 , 3, 341-5 | 3 | 71 |
| 6 | Optimizing Anthracycline Therapy for Node Positive Breast Cancer. <i>American Journal of Cancer</i> , 2002 , 1, 257-268 | | 6 |

| | | | |
|---|--|------|----|
| 5 | Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. <i>Cancer Treatment Reviews</i> , 2002 , 28, 275-90 | 14.4 | 6 |
| 4 | Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. <i>Annals of Oncology</i> , 2001 , 12, 615-20 | 10.3 | 60 |
| 3 | Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma. <i>Annals of Oncology</i> , 2001 , 12, 1757-9 | 10.3 | 20 |
| 2 | Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. <i>Anticancer Research</i> , 2001 , 21, 789-95 | 2.3 | 16 |
| 1 | Squamous cell carcinoma of the breast. <i>Breast</i> , 2000 , 9, 315-9 | 3.6 | 55 |